Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	396	445	272	158	308	48
Market Cap Growth	63.82%	63.82%	71.57%	-48.52%	536.60%	283.47%
Enterprise Value	387	416	233	97	178	112
Last Close Price	7.32	8.34	6.55	4.59	8.71	11.20
Forward PE	96.00	-	-	-	-	2.95
PS Ratio	14.34	18.85	9.90	15.59	10.74	3.64
PB Ratio	9.90	11.22	4.39	2.11	2.42	-0.73
P/TBV Ratio	-	-	-	2.11	2.42	-
P/FCF Ratio	-	-	-	29.76	-
P/OCF Ratio	-	-	-	29.47	-
EV/Sales Ratio	16.39	17.61	8.49	9.52	6.21	8.43
EV/EBITDA Ratio	-	-	-	22.27	-
EV/EBIT Ratio	-	-	-	23.01	-
EV/FCF Ratio	-	-	-	17.20	-
Debt / Equity Ratio	1.52	1.52	0.71	0.19	0.01	-1.06
Debt / EBITDA Ratio	-	-	-	-	0.18	-
Debt / FCF Ratio	-	-	-	-	0.16	-
Asset Turnover	0.14	0.14	0.19	0.08	0.40	1.22
Quick Ratio	2.35	2.35	1.16	7.58	26.92	0.90
Current Ratio	2.53	2.53	1.18	7.72	27.20	1.11
Return on Equity (ROE)	-207.84%	-207.84%	-67.23%	-26.48%	-28.18%	-
Return on Assets (ROA)	-31.03%	-31.03%	-21.55%	-12.54%	6.70%	-27.52%
Return on Capital (ROIC)	-52.90%	-52.90%	-31.82%	-14.28%	7.27%	-62.18%
Return on Capital Employed (ROCE)	-	-	-	-	6.00%	-
Earnings Yield	-26.64%	-23.70%	-16.95%	-16.90%	-2.78%	-26.41%
FCF Yield	-17.59%	-15.65%	-12.45%	-11.88%	3.36%	-4.08%
Buyback Yield / Dilution	-30.46%	-30.46%	-2.79%	-15.87%	-647.72%	-114.79%

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q